Gotham Asset Management LLC Acquires 36,763 Shares of Bio-Rad Laboratories, Inc. $BIO

Gotham Asset Management LLC boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 41.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 124,626 shares of the medical research company’s stock after buying an additional 36,763 shares during the quarter. Gotham Asset Management LLC owned approximately 0.46% of Bio-Rad Laboratories worth $34,944,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BIO. Capital Research Global Investors acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $117,303,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Bio-Rad Laboratories by 2,271.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock valued at $111,363,000 after purchasing an additional 380,422 shares during the last quarter. Norges Bank bought a new position in Bio-Rad Laboratories in the 2nd quarter valued at approximately $30,987,000. Mangrove Partners IM LLC acquired a new stake in Bio-Rad Laboratories in the third quarter valued at approximately $35,568,000. Finally, Ilex Capital Partners UK LLP boosted its position in Bio-Rad Laboratories by 1,790.3% in the second quarter. Ilex Capital Partners UK LLP now owns 120,885 shares of the medical research company’s stock valued at $29,172,000 after buying an additional 114,490 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Stock Down 0.6%

Shares of NYSE BIO opened at $261.17 on Tuesday. The company has a 50 day simple moving average of $290.85 and a 200 day simple moving average of $300.06. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $343.12. The firm has a market cap of $7.05 billion, a PE ratio of 9.36 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). The business had revenue of $693.20 million for the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The company’s revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.90 earnings per share. On average, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.